Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Latest News
Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Her quippy liberal sweater brand went left. Was it the right choice?
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.gilead.com |
| Audit Risk | 9 |
| Board Risk | 5 |
| Overall Risk | 5 |
| Market Cap | 160.55B |
| Trailing P/E | 17.62 |
| Forward P/E | 13.43 |
| Dividend Rate | 3.28 |
| Dividend Yield | 2.54% |
| Trailing Annual Div. Rate | 3.19 |
| Trailing Annual Div. Yield | 2.44% |
| Trailing EPS | 7.34 |
| Forward EPS | 9.63 |
| Book Value | 18.93 |
| Price-to-Book | 6.83 |
| Enterprise-to-Revenue | 5.81 |
| Enterprise-to-EBITDA | 11.73 |
| Short Ratio | 3.06 |
| Ex-Dividend Date | 06/15/2026 |
| Dividend Date | 06/29/2026 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | 08/04/2026 |
| Earnings Average | -7.25 |
| Earnings Low | -7.93 |
| Earnings High | -6.4 |
| Revenue Average | 7.40B |
| Revenue Low | 7.18B |
| Revenue High | 7.50B |